Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

NCT07661797 | Not Yet Recruiting Phase 1

• 1 other identifier: NTP-LNF2105-001
• Study Type: interventional
• Target: 294
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.

Conditions

Patients With Advanced Solid Tumors

Outcome Measures

Primary Outcomes (2)

• To evaluate of Safety and Tolerability of LNF2105 in Patients with Advanced Solid Tumors

  Numbers of treatment emergent adverse events with severity determined using NCI CTCAE v6.0 after single or multiple doses of LNF2105.

  Approximately 24months

• To confirm Dose Limiting Toxicities (DLT) and determine MTD and RP2D for LNF2105

  Occurrence of Dose Limiting Toxicities as defined in the protocol

  28 days

Secondary Outcomes (11)

• Maximum observed plasma concentration of LNF2105 (ADC), Total Antibody and Free Payload (Cmax)

  Approximately 24 months

• Time to reach Cmax of LNF2105 (ADC), Total Antibody and Free Payload (Tmax)

  24 month

• Total Area Under the plasma concentration-time curve of LNF2105 (ADC), Total Antibody and Free Payload (AUC)

  24 month

• Minimum Plasma Concentration (Cmin) of LNF2105 (ADC), Total Antibody and Free Payload

  24 month

• To evaluate the preliminary antitumor activity of LNF2105: Overall response rate (ORR)

  Approximately 24months

Study Arms (1)

LNF2105

EXPERIMENTAL

The dosage was increased sequentially from 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.0 mg/kg, 3.0 mg/kg, to 4.5 mg/kg.

Drug: LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)

Interventions

LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4) DRUG

The dosage of LNF2105 was increased sequentially from 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.0 mg/kg, 3.0 mg/kg, to 4.5 mg/kg.

LNF2105

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged ≥18 years.
• Patients with advanced solid tumors (including but not limited to urothelial carcinoma, breast cancer, non-small cell lung cancer, ovarian cancer, endometrial cancer, and cervical cancer) that have been histologically or cytologically confirmed as having failed/cannot tolerate/have no standard treatment/are currently unsuitable for standard treatment.
• Able to provide previous Nectin-4 expression testing results or preserved/fresh tumor tissue for Nectin-4 expression testing.
• At least one measurable lesion (CT or MRI long axis ≥ 10 mm, lymph node short axis ≥ 15 mm) according to RECIST v1.1 criteria. For lesions previously treated with radiotherapy, they will only be included as measurable lesions if there has been clear disease progression after radiotherapy.
• The function of vital organs must meet the following requirements (no blood components or cytokines may be used within 14 days prior to the first dose).
• \) ECOG score 0-1. 8) Expected survival ≥ 3 months. 9) Willing to participate and sign informed consent form, and willing to follow the trial treatment protocol and visitation plan.

You may not qualify if:

• Prior treatment with an antibody-drug conjugate (ADC) exhibiting one of the following characteristics: payload as a topoisomerase I inhibitor (TOP 1 inhibitor); antibody target as Nectin-4.
• Patients who received chemotherapy within 3 weeks or radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, or other anti-tumor treatments within 4 weeks prior to first administration of the study drug, excluding the following.
• Patients who received systemic glucocorticoid therapy or any other form of immunosuppressive therapy (equivalent to a prednisone dose \>10 mg/day) within 2 weeks prior to the first dose.
• Patients with primary central nervous system (CNS) malignancies, CNS metastases that have failed local treatment, or carcinomatous meningitis; patients with asymptomatic brain metastases, or stable clinical symptoms such as neurological symptoms and who do not require corticosteroids or other treatments targeting brain metastases for ≥4 weeks may be enrolled.
• Patients with uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
• Patients with known interstitial lung disease (ILD) or non-infectious pneumonia, currently symptomatic or requiring prior systemic glucocorticoid therapy, whose toxicity assessment or management is deemed by the investigator to potentially affect the investigational treatment.
• Patients with a history of organ transplantation or allogeneic bone marrow transplantation, or who received autologous stem cell transplantation within 3 months prior to the first dose.
• Patients who underwent major surgery within 4 weeks prior to the first dose or have not yet recovered from surgery.
• Patients with any of the following laboratory findings.
• Patients with uncontrolled or severe cardiovascular disease, including those who developed NYHA Class II or higher congestive heart failure, unstable angina, myocardial infarction, or other cardiovascular diseases within 6 months prior to the first dose; or those with uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg after treatment).
• Patients with active infections requiring intravenous anti-infective therapy or a history of the following conditions, including but not limited to active autoimmune diseases, severe mental illness, severe endocrine disorders such as severe thyroid dysfunction.
• Patients with the following ocular diseases: a) active infection or corneal ulcer; b) history of corneal transplantation; c) expected contact lens wear during the study period; d) poorly controlled glaucoma; e) poorly controlled or progressive retinopathy, wet macular degeneration, uveitis, papilledema, or optic disc disease; f) or other currently existing ocular diseases that would affect the assessment of ocular toxicity after the trial intervention.
• Glycated hemoglobin (HbA1c) ≥ 8.0%.
• Suffering from severe and/or uncontrolled comorbidities, such as decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, active inflammatory bowel disease, gastrointestinal perforation, intestinal obstruction, or gastrointestinal bleeding.
• Having a bleeding tendency (e.g., abnormal coagulation function tests, clinically significant as determined by the investigator, or clinically significant bleeding symptoms as assessed by the investigator).

Sponsors & Collaborators

• Shandong New Time Pharmaceutical Co., LTD: lead

MeSH Terms

Interventions

arginine decarboxylase

Central Study Contacts

Shaohong Yin

CONTACT

86-15265901803; yinshaohong@lunan.com.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 8, 2026
• First Posted: June 22, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): August 1, 2028
• Last Updated: June 22, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share